Abstracts tagged "systemic sclerosis and toll-like receptors"

Abstract Number: 757 • 2017 ACR/ARHP Annual Meeting
Plasmacytoid Dendritic Cells Activated through TLR8 Promote Systemic Sclerosis
Marie-Dominique Ah Kioon¹, Claudio Tripodo², Alexandra Morquette³, Robert F. Spiera³, Jessica K. Gordon³ and Franck J. Barrat¹, ¹Autoimmunity and Inflammation Program, Hospital for Special Surgery, New York, NY, ²Department of Health Science, Human Pathology, tumor immunology unit, Palermo, Italy, ³Rheumatology, Hospital for Special Surgery, New York, NY
Background/Purpose: Plasmacytoid Dendritic Cells (PDCs) are the key cell type mediating TLR-induced inflammation in several autoimmune diseases such as lupus, dermatomyositis, lichen sclerosus and cutaneous…
Abstract Number: 1009 • 2016 ACR/ARHP Annual Meeting
Plasmacytoid Dendritic Cells Are Activated in Systemic Sclerosis and Contribute to the Disease By Inducing Ifnα and CXCL4
Marie-Dominique Ah Kioon¹, Eliza Pelrine², Robert F. Spiera³, Jessica K. Gordon⁴ and Franck J. Barrat¹, ¹Autoimmunity and Inflammation Program, Hospital for Special Surgery, New York, NY, ²Hospital for Special Surgery, New York, NY, ³Hospital for Special Surgery, Cornell, New York, NY, ⁴Rheumatology, Hospital for Special Surgery, New York, NY
Background/Purpose: Plasmacytoid Dendritic Cells (PDCs) are key immune cells involved with anti-viral responses due to their ability to produce large amount of type I IFN…
Abstract Number: 1919 • 2015 ACR/ARHP Annual Meeting
Genetic Deletion of Toll-like Receptor 4 (Tlr4) Abrogates TGF-β1-Induced Endothelial-to-Mesenchymal Transition (EndoMT) in Murine Pulmonary Endothelial Cells
Peter J. Wermuth¹ and Sergio A. Jimenez², ¹Jefferson Institute of Molecular Medicine, Division of Connective Tissue Diseases and Scleroderma Center, Thomas Jefferson University, Philadelphia, PA, ²Jefferson Institute of Molecular Medicine, Division of Connective Tissue Diseases and Scleroderma Center,Thomas Jefferson University, Philadelphia, PA
Background/Purpose: Systemic sclerosis (SSc) is a systemic autoimmune disease of unknown etiology whose pathogenesis involves the regulation of a diverse range of molecular pathways. The…
Abstract Number: 752 • 2014 ACR/ARHP Annual Meeting
Potential Roles of Toll-like Receptor 4 in the Murine Models of Systemic Sclerosis
Takehiro Takahashi, Yoshihide Asano, Yohei Ichimura, Tetsuo Toyama, Takashi Taniguchi, Shinji Noda, Kaname Akamata and Shinichi Sato, Dermatology, University of Tokyo Graduate School of Medicine, Tokyo, Japan
Background/Purpose: Bleomycin (BLM)-induced fibrosis model and tight skin mice (TSK/+) model are well-established experimental murine models of human systemic sclerosis (SSc). Growing evidence has demonstrated…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].